ha14-1 has been researched along with Cancer of Ovary in 1 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simonin, K | 1 |
| Brotin, E | 1 |
| Dufort, S | 1 |
| Dutoit, S | 1 |
| Goux, D | 1 |
| N'diaye, M | 1 |
| Denoyelle, C | 1 |
| Gauduchon, P | 1 |
| Poulain, L | 1 |
1 other study available for ha14-1 and Cancer of Ovary
| Article | Year |
|---|---|
Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-X Protein; | 2009 |